0RB1 Stock Chart & Stats
€2.70
-€0.01(-0.37%)
At close: 4:00 PM EDT
€2.70
-€0.01(-0.37%)
Day’s Range― - ―
52-Week Range€2.34 - €3.29
Previous CloseN/A
Volume465.00
Average Volume (3M)286.00
Market Cap
€219.01M
Enterprise Value€291.18
Total Cash (Recent Filing)€21.58M
Total Debt (Recent Filing)€103.27M
Price to Earnings (P/E)49.3
Beta0.26
Next Earnings
Nov 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding82,883,400
10 Day Avg. Volume278
30 Day Avg. Volume286
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)0.96
Price to Sales (P/S)0.63
P/FCF Ratio-15.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.15
Revenue Forecast (FY)€358.95M
Bulls Say, Bears Say
Bulls Say
Diversified Business Model (Products + CDMO)The dual revenue streams—commercialized pharmaceuticals and CDMO services—create structural diversification. CDMO contracts can smooth cycles, monetize manufacturing capacity and build long-term client relationships, supporting steady revenue and utilization over the medium term.
Historical Revenue Expansion (2020–2024)Consistent top-line growth through 2024 indicates an established commercial footprint and product adoption. This track record implies the company has repeatable sales and distribution capabilities that can support recovery and growth once market headwinds abate.
Moderate Leverage And Equity GrowthHistorically moderate debt levels and gradual equity growth provide balance-sheet resilience. That financial flexibility supports investment in manufacturing, R&D or contract wins and reduces short-term refinancing pressure compared with highly levered peers.
Bears Say
Sharp Revenue Decline In 2025A 20% drop in revenue is a material structural setback that weakens operating leverage and may reflect lost demand, pricing pressure or market-share erosion. Sustained lower sales reduce capacity utilization and cash generation, impairing reinvestment and long-term competitiveness.
Negative And Volatile Free Cash FlowA sharp FCF decline undermines the firm's ability to fund operations, capex and R&D internally. Volatility (negative in 2021 and 2025) elevates refinancing and liquidity risk, making the company more reliant on external financing or asset sales during downturns.
Compressed Profitability And Weak ReturnsVery low margins and depressed ROE signal weak profitability and limited capacity to generate shareholder returns. Persistently thin operating margins hinder reinvestment, pricing power and resilience to cost inflation, raising structural concerns about long-term earnings quality.
LABORATORIO REIG JOFRE News
0RB1 FAQ
What was LABORATORIO REIG JOFRE S.A.’s price range in the past 12 months?
LABORATORIO REIG JOFRE S.A. lowest share price was €2.34 and its highest was €3.29 in the past 12 months.
What is LABORATORIO REIG JOFRE S.A.’s market cap?
LABORATORIO REIG JOFRE S.A.’s market cap is €219.01M.
When is LABORATORIO REIG JOFRE S.A.’s upcoming earnings report date?
LABORATORIO REIG JOFRE S.A.’s upcoming earnings report date is Nov 13, 2026 which is in 99 days.
How were LABORATORIO REIG JOFRE S.A.’s earnings last quarter?
Currently, no data Available
Is LABORATORIO REIG JOFRE S.A. overvalued?
According to Wall Street analysts LABORATORIO REIG JOFRE S.A.’s price is currently Overvalued.
Does LABORATORIO REIG JOFRE S.A. pay dividends?
LABORATORIO REIG JOFRE S.A. does not currently pay dividends.
What is LABORATORIO REIG JOFRE S.A.’s EPS estimate?
LABORATORIO REIG JOFRE S.A.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LABORATORIO REIG JOFRE S.A. have?
LABORATORIO REIG JOFRE S.A. has 82,883,400 shares outstanding.
What happened to LABORATORIO REIG JOFRE S.A.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of LABORATORIO REIG JOFRE S.A.?
Currently, no hedge funds are holding shares in GB:0RB1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
LABORATORIO REIG JOFRE S.A.
Laboratorio Reig Jofre, S.A. is a pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of a diverse range of medicines and nutritional supplements. Its extensive portfolio encompasses prescription drugs, over-the-counter (OTC) products, medical devices, and cosmetics. The company's offerings are categorized into several key areas: advanced pharmaceutical technologies, which include antibiotics and injectable formulations; specialized healthcare solutions targeting dermatological, musculoskeletal (joint health and pain), women's health, respiratory/ENT, and pediatric needs; and consumer health items marketed under its Forté Pharma brand. Furthermore, Laboratorio Reig Jofre provides contract development and manufacturing (CDMO) as well as contract manufacturing organization (CMO) services. Founded in 1929 and headquartered in Sant Joan Despí, Spain, the company sells its products directly in seven countries and collaborates with business partners to reach approximately 70 other nations. It operates as a subsidiary of Reig Jofre Investments SL.
Technical Analysis
Almirall
―
Clinica Baviera
―
Faes Farma
―
Grifols
―
Laboratorios Farmaceuticos Rovi
―